These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 18757658)

  • 1. Screening for adverse pregnancy outcome by ductus venosus Doppler at 11-13+6 weeks of gestation.
    Maiz N; Valencia C; Emmanuel EE; Staboulidou I; Nicolaides KH
    Obstet Gynecol; 2008 Sep; 112(3):598-605. PubMed ID: 18757658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death.
    Spencer K; Cowans NJ; Avgidou K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Oct; 28(5):637-43. PubMed ID: 16952214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
    Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
    Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal serum free-beta-chorionic gonadotrophin, pregnancy-associated plasma protein-A and fetal nuchal translucency thickness at 10-13(+6) weeks in relation to co-variables in pregnant Saudi women.
    Ardawi MS; Nasrat HA; Rouzi AA; Qari MH; Al-Qahtani MH; Abuzenadah AM
    Prenat Diagn; 2007 Apr; 27(4):303-11. PubMed ID: 17269128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes.
    Krantz D; Goetzl L; Simpson JL; Thom E; Zachary J; Hallahan TW; Silver R; Pergament E; Platt LD; Filkins K; Johnson A; Mahoney M; Hogge WA; Wilson RD; Mohide P; Hershey D; Wapner R;
    Am J Obstet Gynecol; 2004 Oct; 191(4):1452-8. PubMed ID: 15507982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery.
    Spencer K; Cowans NJ; Molina F; Kagan KO; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Feb; 31(2):147-52. PubMed ID: 17992705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial).
    Dugoff L; Hobbins JC; Malone FD; Porter TF; Luthy D; Comstock CH; Hankins G; Berkowitz RL; Merkatz I; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Vidaver J; D'Alton ME
    Am J Obstet Gynecol; 2004 Oct; 191(4):1446-51. PubMed ID: 15507981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses.
    Spencer K; Cowans NJ; Avgidou K; Molina F; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Jan; 31(1):15-9. PubMed ID: 17999381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
    Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
    Chen X; Chang Y; Cui HY; Ren CC; Yu BY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of serum markers in first-trimester down syndrome screening.
    Canick JA; Lambert-Messerlian GM; Palomaki GE; Neveux LM; Malone FD; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Saade GR; Berkowitz RL; Dar P; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2006 Nov; 108(5):1192-9. PubMed ID: 17077242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fetal nuchal translucency and ductus venosus Doppler at 11-14 weeks of gestation in the detection of major congenital heart defects.
    Favre R; Cherif Y; Kohler M; Kohler A; Hunsinger MC; Bouffet N; Tanghe M; Cancellier M; Nisand I
    Ultrasound Obstet Gynecol; 2003 Mar; 21(3):239-43. PubMed ID: 12666217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
    Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
    Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
    Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal serum pregnancy-associated plasma protein A and fetal nuchal translucency thickness for the prediction of fetal trisomies in early pregnancy.
    Brizot ML; Snijders RJ; Bersinger NA; Kuhn P; Nicolaides KH
    Obstet Gynecol; 1994 Dec; 84(6):918-22. PubMed ID: 7526305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ductus venosus studies in fetuses at high risk for chromosomal or heart abnormalities: relationship with nuchal translucency measurement and fetal outcome.
    Bilardo CM; Müller MA; Zikulnig L; Schipper M; Hecher K
    Ultrasound Obstet Gynecol; 2001 Apr; 17(4):288-94. PubMed ID: 11339183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for trisomy 18 by maternal age, fetal nuchal translucency, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
    Kagan KO; Wright D; Maiz N; Pandeva I; Nicolaides KH
    Ultrasound Obstet Gynecol; 2008 Sep; 32(4):488-92. PubMed ID: 18726925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-trimester screening for chromosomal abnormalities.
    Nicolaides KH
    Semin Perinatol; 2005 Aug; 29(4):190-4. PubMed ID: 16104667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of Rhesus status on first-trimester pregnancy screening markers free beta human chorionic gonadotropin, pregnancy-associated plasma protein-A and nuchal translucency.
    Cowans NJ; Stamatopoulou A; Spencer K
    Prenat Diagn; 2009 May; 29(5):505-7. PubMed ID: 19222026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.